IPF is not considered an immune-driven disease. Despite this, recent discoveries pertaining to myeloid-derived suppressor cells (MDSC), T regulatory cells, and innate lymphoid cells (ILCs) in IPF have enhanced interest around the role that the immune system might play in disease initiation and progression.
Attend this expert led workshop to:
• Comprehensively explore these discoveries as well as the putative role of the lung immune response in regulating or modulating the lung microbiome
• Understand the role MDSC’s take in fibrotic niches in inducing an excessive immune response and ultimately IPF development
• Harness the lessons learnt, and opportunities they present, from a variety of therapeutic areas, notably oncology
Cory M. Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center
The purpose of this workshop is to consider strategies to generate effective pre-clinical data packages to support development of novel therapeutics for IPF. The discussion will consider drug
discovery within the context of the current standard of care for this disorder. Strategies will reflect impact of advances related to molecular biology and pathophysiology of IPF as well as pros and
cons of pharmacology models of the disease.
Gain a greater understanding of:
• Challenges of pharmacology models of IPF
• Emerging opportunities in molecular biology of IPF that can support a pre-clinical data set
• Current R&D landscape and its impact on requirements for a successful pre-IND package for novel IPF therapeutics
A. Bruce Montgomery, Chief Executive Officer, Genoa Pharmaceuticals
Clifford D. Wright, Ph.D, Principal, RespirPharm Solutions LLC